Skip to content
Home/Companies/MedTech/PathXL

PathXL

MedTech·United Kingdom·Exited 2016·Held 4yr
Entry
2012
Hold
4yr
Exit
2016

Who owns PathXL?

PathXL is a British MedTech company, now owned by Royal Philips, which acquired it in 2016 from Clarendon Fund Managers.

Hand-verified · updated 2026-07-08

Open JSON · CC-BY
Clarendon Fund Managers
Investor
Clarendon Fund Managers
Co-Fund NI · 2012 · VC

Key facts

HQUnited Kingdom
SectorMedTech
StatusAcquired
Exit Type
Trade Sale
Buyer
Royal Philips
Exit Year
2016

More from Co-Fund NI

Other portfolio companies in the same fund.

GenoME Diagnostics
GenoME Diagnostics
Active
BiotechUK· 2023
Kinsetsu
Active
SaaSUK· 2023
Amply
Amply
Active
BiotechUK· 2022
Angoka
Angoka
Active
CybersecurityUK· 2022
Aramune Technologies
Aramune Technologies
Active
BiotechUK· 2022
CV6 Therapeutics
CV6 Therapeutics
Active
BiotechUK· 2022

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany

Questions

Who owns PathXL?

PathXL is now owned by Royal Philips, which acquired it in 2016 from Clarendon Fund Managers.

When did Royal Philips acquire PathXL?

Royal Philips acquired PathXL in 2016, buying from Clarendon Fund Managers.

Who did PathXL sell to?

Clarendon Fund Managers sold PathXL to Royal Philips in 2016 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue